Guerri-GuttenbergRCastillaRCaoGAzzatoFAmbrosioGMileiJ. Coronary intimal thickening begins in fetuses and progresses in pediatric population and adolescents to atherosclerosis. Angiology. 2019;71:32–9.
2.
GavriliS. Prognostic implications and future associations of coronary intimal thickening in fetuses/neonates. Angiology. 2020;71:291.
3.
YuFLiJHuangQCaiH. Increased peripheral blood visfatin concentrations may be a risk marker of coronary artery disease: a meta-analysis of observational studies. Angiology. 2018;69:825–34.
4.
NazSHSandhuQSHAkhtarAZafarUKhalidASaeedM. Serum levels of visfatin and interleukin-6 in non-obese versus obese men with coronary artery disease. J Coll Physicians Surg Pak. 2017;27:71–4.
5.
DarabiFAghaeiMMovahedianAElahifarAPourmoghadasASarrafzadeganN. Association of serum microRNA-21 levels with visfatin, inflammation, and acute coronary syndromes. Heart Vessels. 2017;32:549–57.
6.
BrianaDDMalamitsi-PuchnerA. Visfatin: a risk marker for a plethora of diseases in adults and infants. Angiology. 2019;70:987.
7.
DahlTBYndestadASkjellandM. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and in plaque destabilization. Circulation. 2007;115:972-80.
8.
SommerGKralischSKlotingN. Visfatin is a positive regulator of MCP-1 in human adipocytes in vitro and in mice in vivo. Obesity (Silver Spring). 2010;18:1486-92.
